Plerixafor

• Description:

  Plerixafor (AMD 3100) is a selective CXCR4 antagonist with an IC50 of 44 nM. Plerixafor, an immunostimulant and a hematopoietic stem cell (HSC) mobilizer, is an allosteric agonist of CXCR7. Plerixafor inhibits HIV-1 and HIV-2 replication with an EC50 of 1-10 nM[1][2][3][4][7].

• Product Name Alternative:

  AMD 3100; JM3100; SID791

• UNSPSC:

  12352005

• Hazard Statement:

  H302, H315, H319, H335

• Target:

  CXCR; HIV

• Type:

  Reference compound

• Related Pathways:

  Anti-infection; GPCR/G Protein; Immunology/Inflammation

• Applications:

  COVID-19-anti-virus

• Field of Research:

  Cancer; Infection; Endocrinology; Inflammation/Immunology

• Assay Protocol:

  https://www.medchemexpress.com/Plerixafor.html

• Purity:

  99.90

• Solubility:

  DMSO : 1.92 mg/mL (ultrasonic; warming; adjust pH to 7 with 1 M HCl; heat to 60°C) |Ethanol : 50 mg/mL (ultrasonic)

• Smiles:

  C1(CN2CCCNCCNCCCNCC2)=CC=C(C=C1)CN3CCNCCCNCCNCCC3

• Molecular Formula:

  C28H54N8

• Molecular Weight:

  502.78

• Precautions:

  H302, H315, H319, H335

• References & Citations:

  [1]Zabel BA, et al. Elucidation of CXCR7-mediated signaling events and inhibition of CXCR4-mediated tumor cell transendothelial migration by CXCR7 ligands. J Immunol. 2009 Sep 1;183 (5) :3204-11.|[2]Mercurio L, et al. Targeting CXCR4 by a selective peptide antagonist modulates tumor microenvironment and microglia reactivity in a human glioblastoma model. J Exp Clin Cancer Res. 2016 Mar 25;35:55.|[3]Yang J, et al. Continuous AMD3100 Treatment Worsens Renal Fibrosis through Regulation of Bone Marrow Derived Pro-Angiogenic Cells Homing and T-Cell-Related Inflammation. PLoS One. 2016 Feb 22;11 (2) :e0149926.|[4]Chu PY, et al. CXCR4 Antagonism Attenuates the Development of Diabetic Cardiac Fibrosis. PLoS One. 2015 Jul 27;10 (7) :e0133616.|[5]De Clercq E, et al. Mozobil® (Plerixafor, AMD3100), 10 years after its approval by the US Food and Drug Administration. Antivir Chem Chemother. 2019 Jan-Dec;27:2040206619829382.|[6]Seki JT, et al. Chemical Stability of Plerixafor after Opening of Single-Use Vial. Can J Hosp Pharm. 2017 Jul-Aug;70 (4) :270-275.|[7]Schols D, et al. HIV co-receptor inhibitors as novel class of anti-HIV drugs. Antiviral Res. 2006 Sep;71 (2-3) :216-26.|[8]Zheng J, et al. Toward Normalization of the Tumor Microenvironment for Cancer Therapy. Integr Cancer Ther. 2019;18:1534735419862352.

• Shipping Conditions:

  Room Temperature

• Storage Conditions:

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category:

  Reference compound1

• Clinical Information:

  Launched

• Isoform:

  CXCR4; CXCR7; HIV-1; HIV-2

• Citation 01:

  ACS Infect Dis. 2023 Nov 10;9 (11) :2105-2118.|Acta Biomater. 2024 Jul 17:S1742-7061 (24) 00395-7.|Acta Biomater. 2024 Mar 15:177:414-430.|Acta Pharmacol Sin. 2025 Oct 17.|Adv Funct Mater. 2024 Dec 23.|Adv Sci (Weinh) . 2025 Jun 19:e00225.|Andrology. 2023 Feb;11 (2) :295-306.|Bioact Mater. 2021 Jan 7;6 (7) :2039-2057.|Biochem Biophys Res Commun. 2021 Jan 1;534:337-342.|Biochem Pharmacol. 2025 Jun:236:116852.|Biomaterials. 2025 Jan 3:317:123091.|Biomed Pharmacother. 2020 Oct:130:110610.|Biomolecules. 2024 Sep 25;14 (10) :1206.|bioRxiv. 2025 Oct 7.|BMC Complement Altern Med. 2018 Dec 12;18 (1) :330. |Br J Haematol. 2023 May;201 (3) :459-469.|Cancer Lett. 2022 Oct 7;551:215944.|Cardiovasc Res. 2025 Nov 11:cvaf215.|Cell Death Dis. 2017 Jan 19;8 (1) :e2560. |Cell Death Dis. 2022 Feb 4;13 (2) :118.|Cell Death Dis. 2023 Mar 28;14 (3) :219.|Cell Death Discov. 2025 Apr 8;11 (1) :156.|Cell Mol Immunol. 2020 Mar;17 (3) :283-299.|Cell Mol Life Sci. 2024 Mar 13;81 (1) :132.|Cell Physiol Biochem. 2018;46 (3) :890-906. |Cell Rep Med. 2025 Jul 15;6 (7) :102211.|Cell Signal. 2020 Feb;66:109488.|Cell Tissue Res. 2020 Jun;380 (3) :469-486.|Cell Transplant. 2022 Jan-Dec;31:9636897221129171.|Cells. 2019 Jul 22;8 (7) :761.|Cells. 2022 Jan 4;11 (1) :155.|Chem Eng J. 2025 Oct 15.|Chinese Journal of Tissue Engineering Research . 2014,18 (45) : 7327-7332.|Drug Des Devel Ther. 2022 Jan 6;16:67-81.|Exp Ther Med. 2021 Sep;22 (3) :1037.|Fertil Steril. 2020 May;113 (5) :1067-1079.e5.|Immunity. 2024 Feb 13;57 (2) :364-378.e9.|Int Immunopharmacol. 2024 Nov 30:144:113707.|Int J Biol Sci. 2017 May 5;13 (5) :604-614.|Int J Mol Sci. 2023 Aug 13;24 (16) :12740.|Int J Mol Sci. 2024 Jul 1;25 (13) :7254.|Int J Mol Sci. 2024 May 4;25 (9) :5018.|Int J Nanomedicine. 2023 Jul 31:18:4329-4346.|Invest Ophthalmol Vis Sci. 2025 Aug 1;66 (11) :23.|J Cell Mol Med. 2025 Jan;29 (2) :e70352.|J Diabetes Complications. 2020 Oct;34 (10) :107654.|J Immunother Cancer. 2024 Dec 4;12 (12) :e009629.|J Mater Chem B. 2018 Apr 7;6 (13) :1951-1964.|J Nanobiotechnology. 2025 Aug 29;23 (1) :592.|J Oncol. 2021 Oct 8:2021:5584406.|J Periodontol. 2025 Jul 8.|J Steroid Biochem Mol Biol. 2021 Sep:212:105926.|J Transl Med. 2023 Sep 5;21 (1) :593.|Kaohsiung J Med Sci. 2022 Feb;38 (2) :120-128.|Leukemia. 2025 Aug 15.|Ludwig maxime clinic. University of Munich. 2019 Apr.|Mol Med Rep. 2020 Oct;22 (4) :3201-3212.|Nano Today. 2022, 47: 101689.|Nat Cell Biol. 2024 Aug;26 (8) :1346-1358.|Oncogene. 2019 Jun;38 (25) :5021-5037. |Oncol Lett. 2018 Sep;16 (3) :3976-3982. |Patent. US20200360478A1.|Phytomedicine. 2025 Jun:141:156667.|PLoS One. 2021 Mar 1;16 (3) :e0247707.|Res Sq. 2025 Aug 07.|Res Sq. 2025 Mar 16.|Research Square Preprint. 2021 Aug.|Research Square Preprint. 2022 Jul.|Research Square Preprint. 2023 Oct 23.|SSRN. 2025 Jan 13.|SSRN. 5 Feb 2022.|Stem Cell Res Ther. 2022 Feb 23;13 (1) :79.|Stem Cells Int. 2020 Jul 7;2020:1498315.|Theranostics. 2021 Jan 1;11 (6) :2612-2633.|Transl Stroke Res. 2022 Apr;13 (2) :276-286.|Universität Hamburg. Informatics and Natural Sciences. 2021 Mar 19.|University of Zagreb. 2024 May 23.|Uppsala University. Department of Pharmaceutical Biosciences. 2022 Feb.|Adv Funct Mater. 2020, 2000309.|Am J Physiol Cell Physiol. 2025 Apr 1;328 (4) :C1260-C1278.|Anticancer Drugs. 2017 Oct;28 (9) :935-942.|Brain Behav Immun. 2017 Jan:59:322-332.|J Neuroinflammation. 2025 Jun 28;22 (1) :169.|Mater Today Bio. 2024 Sep 1:28:101222.|Mol Ther-Nucl Acids. 2023 Mar 9.|Oncogene. 2022 Oct;41 (41) :4633-4644.|Oxid Med Cell Longev. 2021 Aug 2;2021:9993240.|Patent. US20190133998A1.|Pharmaceutics. 2021 Mar 24;13 (4) :439.|Proc Natl Acad Sci U S A. 2025 Mar 18;122 (11) :e2425795122.|Ruprecht-Karls-University Heidelberg. 2023 Aug 3.

• CAS Number:

  [110078-46-1]